Applying stem cell technology for cardiovascular indications is not just an idea anymore.

CardioCell is currently in clinical trials using stem cells to develop “off-the-shelf” products for cardiovascular indication. The company is exploring unmet medical needs in:

  • Acute Myocardial Infarction (AMI)
  • Chronic Heart Failure (CHF)
  • Peripheral Artery Disease (PAD)

For clinical trials, CardioCell is using cGMP allogeneic stem cells derived from the bone marrow of healthy volunteers. These cells are manufactured in a licensed cGMP-compliant facility.

CardioCell’s scientific board members and clinical trial principal investigators collaborated on a peer-reviewed paper published in the Journal of Cardiovascular Medicine. For more detail, CLICK HERE.
Clinical Trials Update
CardioCell recently reported positive results from the first Phase IIa clinical trial using IV administration of stem cells for chronic heart failure indications. CLICK HERE.
Latest News
CardioCell retained Objective Capital Partners to help manage current phase of accelerated growth. READ MORE HERE.